Back

Large-scale genome-wide association study to determine the genetic underpinnings of female genital tract polyps

Pathare, A. D. S.; Pujol-Gualdo, N.; Rukins, V.; Dzigurski, J.; Peters, M.; Team, E. B. R.; Mägi, R.; Salumets, A.; Saare, M.; Laisk, T.

2024-01-30 obstetrics and gynecology
10.1101/2024.01.29.24301773
Show abstract

STUDY QUESTIONCan a large-scale genome-wide association study (GWAS) meta-analysis identify the genomic risk loci and associated candidate genes for female genital tract (FGT) polyps, provide insights into the mechanism underlying their development, and inform potential overlap with other traits, including endometrial cancer? SUMMARY ANSWERGWAS meta-analysis of FGT polyps highlighted the potentially shared mechanisms between polyp development and cancerous processes. WHAT IS KNOWN ALREADYSmall-scale candidate gene studies have focused on biological processes such as estrogen stimulation and inflammation to clarify the biology behind FGT polyps. However, the exact mechanism for the development of polyps is still elusive. At the same time, a genome-wide approach, which has become the gold standard in complex disease genetics, has never been used to uncover the genetics of the FGT polyps. STUDY DESIGN, SIZE, DURATIONWe performed a genome wide association study (GWAS) meta-analysis including a total of 25,100 women with FGT polyps (International Classification of Disease, ICD-10 diagnosis code N84) and 207,193 female controls (without N84 code) of European ancestry from the FinnGen study (11,092 cases and 94,394 controls) and the Estonian Biobank (EstBB, 14,008 cases and 112,799 controls). PARTICIPANTS/MATERIALS, SETTING, METHODSA meta-analysis and functional annotation of GWAS signals were performed to identify and prioritise genes in associated loci. To determine associations with other phenotypes, we performed a look-up of associated variants across multiple traits and health conditions, a genetic correlation analysis, and a phenome-wide association study (PheWAS) with ICD10 diagnosis codes. MAIN RESULTS AND THE ROLE OF CHANCEOur GWAS meta-analysis revealed ten significant (P < 5 x 10-8) genomic risk loci. Two signals, rs2277339 (P = 7.6 x 10-10) and rs1265005 (P = 1.1 x 10-9) (in linkage disequilibrium (LD) with rs805698 r2 = 0.75), are exonic missense variants in PRIM1, and COL17A1 genes, respectively. Based on the literature, these genes may play a role in cellular proliferation. Several of the identified genomic loci had previously been linked to endometrial cancer and/or uterine fibroids. Thus, highlighting the potentially shared mechanisms underlying tissue overgrowth and cancerous processes, which may be relevant to the development of polyps. Genetic correlation analysis revealed a negative correlation between sex hormone-binding globulin (SHBG) and the risk of FGT polyps (rg = -0,21, se = 0.04, P = 2.9 x 10-6), and on the phenotypic level (PheWAS), the strongest associations were observed with endometriosis, leiomyoma of the uterus and excessive, frequent and irregular menstruation. LARGE SCALE DATAThe complete GWAS summary statistics will be made available after publication through the GWAS Catalogue (https://www.ebi.ac.uk/gwas/). LIMITATIONS, REASONS FOR CAUTIONIn this study, we focused broadly on polyps of FGT and did not differentiate between the polyp subtypes. The prevalence of FGT polyps led us to assume that most women included in the study had endometrial polyps. Further study on the expression profile of FGT polyps could complement the GWAS study to substantiate the functional importance of the identified variants. WIDER IMPLICATIONS OF THE FINDINGSThe study findings have the potential to significantly enhance our understanding of the genetic mechanisms involved, paving the way for future functional follow-up, which in turn could improve the diagnosis, risk assessment, and targeted treatment options, since surgery is the only line of treatment available for diagnosed polyps. TRIAL REGISTRATION NUMBERNot applicable

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Human Reproduction
based on 11 papers
Top 0.1%
16.2%
2
eLife
based on 262 papers
Top 0.9%
10.7%
3
Nature Communications
based on 483 papers
Top 10%
8.0%
4
Nature
based on 58 papers
Top 0.9%
4.7%
5
BMC Medicine
based on 155 papers
Top 3%
4.7%
6
Scientific Reports
based on 701 papers
Top 39%
4.7%
7
PLOS ONE
based on 1737 papers
Top 70%
4.7%
50% of probability mass above
8
Communications Biology
based on 36 papers
Top 0.1%
4.7%
9
International Journal of Molecular Sciences
based on 39 papers
Top 0.4%
3.1%
10
Frontiers in Genetics
based on 32 papers
Top 0.7%
3.1%
11
Cell Reports Medicine
based on 49 papers
Top 1%
3.0%
12
iScience
based on 74 papers
Top 1%
2.6%
13
Human Molecular Genetics
based on 28 papers
Top 1%
2.4%
14
Computational and Structural Biotechnology Journal
based on 14 papers
Top 0.5%
2.4%
15
Clinical Cancer Research
based on 22 papers
Top 3%
1.4%
16
BMC Cancer
based on 21 papers
Top 3%
1.4%
17
Journal of Clinical Medicine
based on 77 papers
Top 12%
1.3%
18
International Journal of Obesity
based on 17 papers
Top 2%
1.3%
19
Journal of Medical Genetics
based on 22 papers
Top 2%
0.8%
20
The Journal of Clinical Endocrinology & Metabolism
based on 26 papers
Top 3%
0.8%
21
Cancers
based on 57 papers
Top 6%
0.8%
22
Nature Genetics
based on 72 papers
Top 8%
0.8%
23
Cancer Epidemiology, Biomarkers & Prevention
based on 14 papers
Top 4%
0.7%
24
Hypertension
based on 20 papers
Top 3%
0.7%
25
Cells
based on 14 papers
Top 2%
0.7%
26
European Journal of Human Genetics
based on 25 papers
Top 3%
0.7%
27
BMJ Open
based on 553 papers
Top 52%
0.7%
28
Pain
based on 15 papers
Top 1%
0.7%